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Tyypin 2 diabetes on aiemmissa tutkimuksissa yhdistetty huonoon eturauhassyövän 
ennusteeseen. Hyperglykemian vaikutus eturauhassyövän etenemiseen on kuitenkin epäselvä. 
Tutkimme hyperglykemian ja eturauhassyöpäkuolleisuuden yhteyttä. Kohorttina käytimme 1,770 
miestä, joilla oli diagnosoitu eturauhassyöpä suomalaisen eturauhassyövän seulontatutkimuksen 
(FinRSPC) aikana vuosina 1995-2009. Näille osallistujille oli saatavissa myös tietoa 
paastoverensokerimittauksista Fimlabin tietokannasta. 1,398 osallistujalle oli saatavissa tietoa 
HbA1c-mittauksista. Tiedot diabeteslääkkeiden käytöstä saatiin Kansaneläkelaitoksen (Kela) 
reseptitietokannasta. Aikariippuvaista Coxin regressioanalyysiä hyödynnettiin riskisuhteiden ja 95% 
luottamusvälien estimointiin eturauhassyöpäkuoleman suhteen diabeettisilla, heikentyneen 
glukoosinsietokyvyn omaavilla (IGT) ja normoglykeemisillä miehillä. 
 
Diagnoosin jälkeisen 9.9 vuoden mediaaniseuranta-ajan aikana 182 miestä kuoli 
eturauhassyöpään. Kasvaimen levinneisyysasteen, PSA-tason diagnoosin aikaan, ja Gleason 
pisteytyksen vakioimisen jälkeen diabeettiset paastosokeriarvot eturauhassyöpädiagnoosin jälkeen 
liittyivät korkeampaan eturauhassyöpäkuoleman riskiin verrattuna normoglykeemisiin miehiin. 
Kohonneen riskin yhteys oli suurin osallistujilla, joilla oli diagnoosivaiheessa paikallinen syöpä. 
Riskin kohoaminen oli havaittavissa jopa viisi vuotta edeltävästi otetuissa diabeettisissa 
verensokeritasoissa. Diabeettiset verensokeritasot ennen diagnoosia eivät olleet yhteydessä 
kohonneeseen eturauhassyöpäkuoleman riskiin. 
 
Tutkimuskohorttimme viittaa siihen, että eturauhassyöpäpotilailla, joilla on diabeettinen 
paastoverensokeritaso, on korkeampi tautispesifinen kuolleisuus. 
 
 
 
Avainsanat: glukoosi, glykatoitunut hemoglobiini, eturauhassyöpä, eloonjääminen 
 
Tämän julkaisun alkuperäisyys on tarkastettu julkaisevan tahon puolesta osana normaalia artikkelin 
hyväksymisprosessia. 
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ABSTRACT 
 
Introduction: Diabetes mellitus has been linked with adverse prostate cancer (PCa) outcomes. 
However, role of hyperglycemia in PCa progression is unclear. We evaluated the link between 
hyperglycemia and PCa survival among Finnish PCa patients. 
Methods: The study cohort included 1,770 men with data on fasting glucose and diagnosed with 
PCa within the Finnish Randomized Study of Screening for PCa in 1995-2009. Additionally, 1,398 
men had data on glycated haemoglobin (HbA1c). Information on fasting glucose and HbA1c 
measurements was obtained from the regional laboratory database. Antidiabetic medication use 
was obtained from the prescription database of the Social Insurance Institution (SII). Time-
dependent Cox regression analysis was used to estimate hazard ratios (HRs) and 95% confidence 
intervals for PCa death among diabetic, glucose intolerant (IGT), and normoglycemic men.  
Results: During median follow-up of 9.9 years after the diagnosis, 182 men died from PCa. After 
adjustment for tumor stage, Gleason grade and PSA level at diagnosis, diabetic fasting glucose 
level after PCa diagnosis was associated with elevated risk of PCa death compared to 
normoglycemic men (HR 1.67 95% CI 1.18-2.36). The risk association was strongest among 
participants with localized cancer at diagnosis; HR 2.39, 95% CI 1.45-3.93. The risk elevation was 
observed for glucose measurements taken up to five years earlier. Diabetic glucose levels 
measured before the diagnosis were not associated with PCa death. 
Conclusion: Our study cohort suggests an increased risk of PCa death in men with diabetic fasting 
blood glucose levels, supporting the role of hyperglycemia as risk factor for PCa progression. 
 
Running head: blood glucose and prostate cancer 
 
Keywords: Glucose, Glycated haemoglobin, Prostate Cancer, Survival 
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INTRODUCTION 
 
Type II diabetes has been linked with increased risk of many cancer types, possibly through 
hyperglycaemia and hyperinsulinemia (1). For prostate cancer (PCa), the findings are more 
controversial. Several studies have found a decreased risk of PCa in men with type II diabetes 
mellitus (2). These results are supported by androgen receptor downregulation by high glucose level 
in androgen-sensitive PCa cells (3). This in theory could mitigate testosterone stimulation of cancer 
cells. However, in other studies hyperinsulinemia, a key feature besides hyperglycaemia in type II 
diabetes, is associated with an increased risk of PCa (4)(5), possibly due to increased IGF-1 activity 
in the prostatic tissue (6). 
Metabolic syndrome and obesity likely increase PCa progression and mortality (7). Obesity has also 
been linked to more aggressive PCa subtypes (8). However, knowledge on the role of individual 
components of metabolic syndrome is insufficient. Especially data on hyperglycaemia, a key 
component of type II diabetes and metabolic syndrome, and its correlation to PCa progression and 
mortality is scarce and contradictory. 
We investigated the association between hyperglycaemia and risk of disease-specific death among 
men with PCa in the Finnish Randomized Study of Screening for PCa. In addition to fasting 
glucose, we analysed glycosylated haemoglobin (HbA1c), which gives an approximate of patient’s 
average blood glucose over 120 days. To assess the effects of anti-diabetic medication on the risk 
association we analysed separately the risk of PCa death both before and after anti-diabetic 
medication in PCa patients prescribed with blood glucose lowering drugs. 
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MATERIALS AND METHODS 
 
Study cohort 
The Finnish Randomized Study of Screening for PCa (FinRSPC) is the largest component of the 
European Randomized Study of Screening for PCa (ERSPC) (9). Between 1996-1999, 80,458 
Finnish men aged 55-69 years at baseline were randomized either to be screened for PCa with 
prostate-specific antigen (PSA) measurements at four-year intervals, or to be followed through 
national registries. Prevalent PCa cases were excluded at baseline. The intervention, completed in 
2008, consisted of three screening rounds. Follow-up for PCa incidence and mortality still 
continues. 
The present study cohort consists of 6,537 men diagnosed with PCa within the FinRSPC study 
population between 1996 and 2009. For each case, information on the date of diagnosis, age, 
tumor stage, Gleason score and treatment as well as date of death (available until end of 2015) 
were obtained from medical files and the nationwide Finnish Cancer Registry. Causes of death 
were obtained from Statistics Finland. Accuracy of information on PCa deaths was validated by the 
FinRSPC cause of death committee (9).  
Information on medication use during 1995-2015 was extracted from the prescription database of 
the Social Insurance Institution (SII), which is a governmental institution to manage social security 
in Finland. SII provides reimbursements for purchases of physician-prescribed drugs. The benefits 
are available to all Finnish citizens. All reimbursed purchases are recorded at individual level in the 
SII database, which covers all of Finland.  Cases were linked to their corresponding medical 
information by personal identification number. The information included records of use of 
antidiabetic medication, antihypertensive drugs, cholesterol-lowering statins, NSAIDs (nonsteroidal 
anti-inflammatory drugs), and aspirin, identified based on ATC codes. 
 
Information on blood glucose level 
Information on measurements of fasting blood and plasma glucose were extracted from the 
records of Fimlab, the largest medical laboratory service provider in the Pirkanmaa area. The 
records cover the results from all laboratory tests by Fimlab laboratories in the Pirkanmaa region. 
The records date back to 1978. Information included fasting blood glucose concentration in the 
plasma or blood and the serum glycosylated haemoglobin concentration (HbA1c). For each 
measurement, the date and the result were available. Fimlab data was linked to the study cohort 
using unique personal identification number. Out of 6,537 men, 1,770 had at least one fasting 
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blood/plasma glucose measurement. Of these 1,048 had at least one measurement before PCa 
diagnosis, 1,676 had measurements after.  In total  1,398 had at least one HbA1c measurement, 
323 before and 1,359 after the diagnosis. Consequently, these men were used in the statistical 
analysis. The individual blood glucose and HbA1c measurements were used to calculate the mean 
for every calendar year. Based on yearly mean fasting glucose level men were categorized to be 
normoglycemic (6.0 mmol/l or below), impaired glucose tolerance (6.1 to 6.9mmol/l), or diabetic 
(7.0mmol/l or over). Corresponding cut points for HbA1c were 38mmol/l or below for 
normoglycemic, 39-47mmol/l for impaired glucose tolerance, and 48mmol/l or higher for diabetes. 
The fasting glucose and HbA1c levels were determined separately for each calendar year between 
1978-2016. 
 
Statistical analysis 
All cases with blood glucose measurements were included in the analysis, regardless of the 
absolute number of measurements. 
Cox regression method was used to estimate hazard ratios (HRs) and 95% confidence intervals 
(95% CI) for PCa death by fasting glucose and HbA1c level. The time metric was years and 
months since PCa diagnosis. Cox regression model was adjusted for age as a continuous variable 
(age-adjusted analysis) and additionally for FinRSPC trial arm, Gleason score and tumor stage at 
diagnosis, use of other drugs (antihypertensive and cholesterol-lowering drugs, NSAIDs and 
aspirin) and PSA at diagnosis (multivariable adjusted analysis) 
The impact of blood glucose on risk of PCa death was estimated separately for glucose levels 
before and after the diagnosis. The same was done for HbA1c. Glucose and HbA1c levels before 
PCa diagnosis were analysed as time-independent variables, taking into account results from all 
measurements performed between 1978 and the year of diagnosis. Glucose and HbA1c levels 
after PCa diagnosis were analysed as time-dependent variable, prospectively updating the level for 
each follow-up year after PCa diagnosis based on available measurements. Men with missing 
values on a given year were categorized into a separate category. 
To evaluate possible effect modification by background variables subgroup analyses were 
performed stratified by tumor clinical characteristics (Gleason score, tumor stage and serum PSA 
at diagnosis), age at diagnosis stratified by median, primary treatment, and medication use. Finally, 
information on antidiabetic drugs use was used to estimate risk of PCa death separately by 
whether blood glucose decreased, increased or stayed the same  after initiation of antidiabetic 
drugs.  
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Lag-time analysis was used to assess the long-term risk of death in PCa patients with elevated 
blood glucose levels. Blood glucose levels from a certain year were lagged forward in the follow-up 
time, e.g. in 5-year lag time analysis measurements from the first follow-up year were analysed on 
the sixth follow-up year. We estimated the risk of PCa death in relation to blood glucose 
measurements taken 1-20 years earlier. This allowed us to estimate how diabetic blood glucose 
measurements in the past predicted the prognosis of PCa patients. Both IGT and diabetic blood 
glucose levels were examined, with normoglycemic men as the reference group. 
Statistical analyses were performed using “IBM SPSS Statistics 23” software. 
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RESULTS 
 
Population characteristics 
At least one fasting blood glucose measurement was available for 1,770 PCa (27.1%) cases, of 
whom 675 died (182 from PCa) during the median follow-up of 9.9 years after the diagnosis (Table 
1). The median follow-up time was slightly shorter in diabetic patients (9.3 versus 10.1). 
The proportion of Gleason 7 and 8-10 tumors was higher among men with diabetes or IGT 
compared to normoglycemic men. Also, the proportion of men with metastatic PCa at diagnosis 
was non-significantly higher in diabetic men (7.9% vs 4.8%, p = 0.064). Similarly, median PSA at 
diagnosis was higher in diabetic men (9.0 vs 7.4 ng/ml, p = 0.003) (Table 1). 
Primary PCa treatment did not significantly differ by blood glucose level. Diabetic men were slightly 
less often managed surgically and received more often endocrine treatment compared to 
normoglycemic men. 
Men with elevated blood glucose levels were more often users of antidiabetic drugs (73.0% in 
diabetic versus 3.5% in normoglycemic men, p <0.001) and antihypertensive drugs (91.7% versus 
81.7%, respectively, p < 0.001) 
Table 1. Population characteristics. 
 Fasting blood glucose 
 Normoglycemic IGT Diabetic 
n of cases 971 484 315 
n of deaths 324 (33.4%) 181 (37.4%) 170 (54.0%) 
n of prostate cancer 
deaths 
76 (7.8%) 57 (11.8%) 49 (15.6%) 
median follow up 
(IQR) 
10.1 (7.0-12.9) 9.8 (6.8-12.5) 9.3 (5.0-13.3) 
Gleason score; n 
(%)* 
   
6 or less 587 (60.4%) 245 (50.6%) 158 (50.2%) 
7 244 (25.1%) 147 (30.4%) 82 (26.0%) 
8-10 111 (11.4%) 77 (15.9%) 60 (19.0%) 
Tumour stage; n (%)    
localized 894 (92.1%) 436 (90.1%) 286 (90.8%) 
metastatic 47 (4.8%) 36 (7.4%) 25 (7.9%) 
Median psa at 
diagnosis (IQR) 
7.40 7.9 9.0** 
Primary treatment; n 
(%) 
   
surgery 330 (34.0%) 154 (31.8%) 85 (27.0%) 
radiation therapy 337 (34.7%) 170 (35.1%) 116 (36.8%) 
endocrine therapy 180 (18.5%) 99 (20.4%) 79 (25.1%) 
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active 
surveillance/watchful 
waiting 
116 (11.9%) 55 (11.4%) 31 (9.84%) 
Medication use; n 
(%) 
   
statins 487 (50.2%) 262 (54.1%) 199 (63.2%) 
antihypertensive 
drugs* 
793 (81.7%) 406 (83.9%) 289 (91.7%) 
antidiabetic drugs* 34 (3.50%) 86 (17.8%) 230 (73.0%) 
nsaid 896 (92.3%) 457 (94.4%) 286 (90.8%) 
aspirin 174 (17.9%) 78 (16.1%) 63 (20.0%) 
Charlson 
comorbidity index; 
median (IQR) 
2 (2-4) 2 (2-4) 3 (2-5)** 
* P < 0.05 for difference by blood glucose level. Calculated with Chi-square test. 
** p <= 0.003 for difference compared to normoglycemic men. Calculated with Mann-Whitney U-test 
 
Risk of PCa death by fasting blood glucose level before and after diagnosis 
The 5-year disease-specific survival proportions were 91.1%, 94.2% and 95.8% among diabetic, 
pre-diabetic and normoglycemic men, respectively (Supplementary figure 1).  Compared to 
normoglycemic men, diabetic blood glucose levels after PCa diagnosis were associated with an 
increased risk of PCa death (multivariable-adjusted HR 1.67 95% CI 1.18-2.36) (Table 2). Similar 
risk increase was observed for IGT and diabetic blood glucose levels before PCa diagnosis only in 
the age-adjusted analysis. 
 
 
 
 
 
 
 
 
 
The increased risk of PCa 
death by diabetic blood 
glucose level post-diagnosis 
Supplementary figure 1. 
Kaplan-Meier curves for 
prostate cancer-specific 
survival stratified by fasting 
blood glucose level. Study 
cohort of 6,537 men with 
prostate cancer from the 
Finnish Randomized Study of 
Prostate Cancer Screening. 
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was observed in men with Gleason 6 or lower and Gleason 7 disease at diagnosis, not among men 
with Gleason 8-10 tumors (Table 2). The risk association between blood glucose level and risk of 
PCa death did not differ by PSA level. 
When stratified by tumor stage, the risk increase by post-diagnostic blood glucose level was 
observed only among men diagnosed with non-metastatic cancer; both IGT and diabetic glucose 
levels were associated with increased risk of PCa death: HR 1.83 (0.89-3.76) for IGT, and HR 2.39 
(1.45-3.93) for diabetic participants in this subgroup. Again, such findings were not observed for 
glucose levels before PCa diagnosis (Table 2). 
Table 2. Risk of prostate cancer death by blood glucose level (normoglycemic level as the reference point). 
Cohort population of 1,770 men with prostate cancer diagnosed within Finnish Randomized Trial of 
Screening for Prostate Cancer. 
 Risk of prostate cancer death 
 Blood glucose before diagnosis Blood glucose after diagnosis 
 HR (95%CI)age-
adjusted 
HR 
(95%CI)multivariable-
adjusted* 
HR (95%CI)age-adjusted HR (95%CI)multivariable-
adjusted* 
 IGT Diabetic IGT Diabetic IGT Diabetic IGT Diabetic 
All 
prostate 
cancer 
cases 
1.60 
(1.02-
2.53) 
2.34 
(1.47-
3.73) 
1.04 
(0.65-
1.68) 
1.69 
(1.05-
2.72) 
1.69 
(0.99-
2.89) 
1.72 
(1.22-
2.42) 
1.50 
(0.87-
2.56) 
1.67 
(1.18-
2.36) 
Gleason 
6 or 
below 
1.49 
(0.47-
4.70) 
1.49 
(0.38-
5.81) 
0.95 
(0.28-
3.17) 
1.24 
(0.30-
5.12) 
1.48 
(0.37-
5.28) 
2.41 
(1.07-
5.45) 
1.45 
(0.36-
5.80) 
2.37 
(1.05-
5.37) 
Gleason 
7 
1.61 
(0.64-
4.10) 
3.63 
(1.53-
8.63) 
1.76 
(0.61-
5.08) 
3.69 
(1.39-
9.77) 
0.79 
(0.16-
3.81) 
2.68 
(1.26-
5.70) 
0.67 
(0.14-
3.17) 
2.26 
(1.12-
4.59) 
Gleason 
8-10 
1.28 
(0.70-
2.36) 
1.21 
(0.62-
2.36) 
0.94 
(0.50-
1.78) 
1.27 
(0.64-
2.52) 
1.17 
(0.58-
2.37) 
1.02 
(0.64-
1.63) 
1.14 
(0.56-
2.34) 
1.01 
(0.63-
1.63) 
Localized 
cancer 
1.82 
(1.03-
3.23) 
2.12 
(1.03-
3.23) 
1.65 
(0.91-
2.96) 
1.52 
(0.82-
2.83) 
2.36 
(1.15-
4.84) 
2.46 
(1.49-
4.05) 
1.83 
(0.89-
3.76) 
2.39 
(1.45-
3.93) 
Metastati
c cancer 
0.49 
(0.23-
1.04) 
1.60 
(0.77-
3.35) 
0.66 
(0.29-
1.52) 
1.78 
(0.77-
4.08) 
1.07 
(0.46-
2.48) 
0.98 
(0.60-
1.61) 
1.05 
(0.45-
2.45) 
0.97 
(0.59-
1.59) 
Serum 
PSA at 
diagnosis 
7.31 or 
below 
2.51 
(0.97-
6.52) 
3.31 
(1.27-
8.63) 
1.83 
(0.64-
5.20) 
1.71 
(0.62-
4.77) 
1.74 
(0.62-
4.89) 
1.92 
(0.98-
3.76) 
1.20 
(0.43-
3.39) 
1.99 
(1.01-
3.91) 
Serum 
PSA at 
diagnosis 
7.32 or 
higher 
1.10 
(0.64-
1.90) 
1.98 
(1.15-
3.41) 
0.69 
(0.40-
1.22) 
1.66 
(0.96-
2.89) 
1.37 
(0.70-
2.67) 
1.38 
(0.92-
2.07) 
1.40 
(0.71-
2.74) 
1.45 
(0.97-
2.17) 
IGT = Impaired glucose tolerance 
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* Calculated with Cox regression model with adjustment for age at PCa diagnosis, tumor Gleason grade and 
stage, PSA at diagnosis and FinRSPC study arm. 
 
In analyses of HbA1c levels (Table 3), some suggestions of increased risk were noted for diabetic 
levels both before and after PCa diagnosis. However, the analyses were limited by low statistical 
power.  
Table 3. Risk of prostate cancer death by glycated haemoglobin level (normoglycemic level as the reference 
point). Cohort population of 1,770 men with prostate cancer diagnosed within Finnish Randomized Trial of 
Screening for Prostate Cancer. 
 Risk of prostate cancer death 
 HbA1c-level before diagnosis HbA1c-level after diagnosis 
 HR (95%CI)age-
adjusted 
HR 
(95%CI)multivariable-
adjusted* 
HR (95%CI) age-
adjusted 
HR (95%CI)multivariable-
adjusted* 
 IGT Diabetic IGT Diabetic IGT Diabetic IGT Diabetic 
All 
prostate 
cancer 
cases 
1.30 
(0.51-
3.32) 
2.14 
(0.89-
5.14) 
1.21 
(0.46-
3.41) 
1.33 
(0.52-
3.41) 
2.02 
(0.87-
4.69) 
1.79 
(0.85-
3.76) 
1.81 
(0.78-
4.22) 
1.86 
(0.88-
3.92) 
Gleason 
6 or 
below 
- - - - 4.50 
(0.54-
37.4) 
3.68 
(0.52-
26.3) 
4.35 
(0.52-
36.2) 
3.80 
(0.53-
27.2) 
Gleason 
7 
1.35 
(0.22-
8.43) 
0.92 
(0.13-
6.61) 
3.09 
(0.32-
29.7) 
4.24 
(0.23-
80.0) 
3.11 
(0.35-
27.9) 
4.51 
(0.63-
32.3) 
3.01 
(0.33-
27.1) 
4.75 
(0.66-
34.0) 
Gleason 
8-10 
1.37 
(0.46-
4.12) 
2.43 
(0.84-
7.02) 
1.62 
(0.50-
5.23) 
2.03 
(0.66-
6.25) 
0.87 
(0.30-
2.52) 
0.97 
(0.40-
2.35) 
0.71 
(0.25-
2.07) 
0.76 
(0.31-
1.85) 
Localized 
cancer 
0.88 
(0.27-
2.90) 
1.24 
(0.40-
3.84) 
1.00 
(0.31-
3.20) 
1.00 
(0.30-
3.31) 
1.59 
(0.61-
4.09) 
1.50 
(0.67-
3.35) 
1.40 
(0.54-
3.61) 
1.64 
(0.73-
3.68) 
Metastati
c cancer 
4.89 
(0.57-
41.6) 
8.86 
(1.11-
71.1) 
5.03 
(0.58-
43.5) 
9.04 
(1.05-
78.0) 
2.48 
(0.31-
19.8) 
2.58 
(0.31-
19.8) 
2.35 
(0.29-
18.8) 
2.21 
(0.31-
15.9) 
Serum 
PSA at 
diagnosis 
7.31 or 
below 
1.06 
(0.19-
5.85) 
2.04 
(0.41-
10.2) 
1.00 
(0.22-
4.65) 
1.00 
(0.20-
4.93) 
1.82 
(0.37-
9.04) 
1.80 
(0.45-
7.26) 
1.08 
(0.22-
5.38) 
1.72 
(0.43-
6.98) 
Serum 
PSA at 
diagnosis 
7.32 or 
higher 
2.06 
(0.67-
6.35) 
2.62 
(0.92-
7.51) 
3.03 
(0.86-
10.6) 
2.90 
(0.86-
9.82) 
1.94 
(0.71-
5.29) 
1.64 
(0.68-
4.00) 
1.95 
(0.71-
5.35) 
1.78 
(0.74-
4.31) 
* Calculated with Cox regression model with adjustment for age at PCa diagnosis, tumor Gleason grade and 
stage, PSA at diagnosis and FinRSPC study arm. 
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Subgroup analysis 
In subgroup analyses no significant effect modification was observed by age at diagnosis or 
primary treatment modality (Table 4). 
Similarly, use of antihypertensive drugs, NSAIDs, or aspirin did not clearly modify the risk 
association between blood glucose and PCa death (Table 4). However, use of antidiabetic 
medication modified the risk association with diabetic glucose level, risk increase being observed 
only among men who did not use antidiabetic drugs, p for interaction = 0.022 in the diabetic group. 
Furthermore, participants with diabetic blood glucose levels after the diagnosis who were 
simultaneously taking statins had an increased risk of PCa death, but among men who were not 
statin users the risk increase was not significant; p for interaction = 0.019. 
Table 4. Risk of prostate cancer death by blood glucose levels in subgroups stratified by age, primary 
treatment and medication use (normoglycemic level as the reference point). Cohort population of 1,770 men 
with prostate cancer diagnosed within Finnish Randomized Trial of Screening for Prostate Cancer. 
 Risk of death overall 
 Blood glucose before diagnosis Blood glucose after diagnosis 
 HR (95%CI)multivariable-adjusted* HR (95%CI)multivariable-adjusted* 
 IGT Diabetic IGT Diabetic 
Age at 
diagnosis 
    
66 or 
younger 
 0.74 (0.25-
2.19) 
1.22 (0.45-3.27) 1.93 (0.84-4.43) 1.54 (0.88-2.71) 
67 or older 1.22 (0.70-
2.12) 
1.84 (1.04-3.25) 1.26 (0.62-2.56) 1.73 (1.12-2.69) 
Primary 
treatment 
    
Surgery 0.54 (0.06-
5.28) 
1.15 (0.11-11.9) 9.42 (0.98-91.0) 8.02 (1.11-58.0) 
Radiation 
therapy 
2.91 (1.08-
7.81) 
1.09 (0.31-3.87) 1.51 (0.49-4.62) 2.00 (0.99-4.06) 
Endocrine 
therapy 
0.82 (0.45-
1.47) 
1.76 (1.01-3.07) 1.01 (0.51-2.03) 1.27 (0.84-1.92) 
Watchful 
waiting 
- - - - 
Medication use    
Antidiabetic drugs    
Any 1.67 (0.47-
5.93) 
2.23 (0.67-7.49) 0.59 (0.22-1.64) 0.64 (0.26-1.57)** 
None 0.96 (0.56-
1.63) 
1.81 (0.95-3.46) 1.48 (0.62-3.58) 1.88 (1.29-2.73)** 
Statins     
Any 1.34 (0.56-
3.19) 
2.38 (1.03-5.48) 1.10 (0.40-3.03) 2.34 (1.24-4.40)*** 
None 1.01 (0.56-
1.84) 
1.70 (0.91-3.18) 2.15 (1.14-4.06) 1.29 (0.85-1.95)*** 
Antihypertensive drugs    
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Any 1.20 (0.70-
2.08) 
1.95 (1.12-3.38) 1.36 (0.75-2.47) 1.60 (1.09-2.37) 
None 0.94 (0.27-
3.27) 
0.87 (0.29-2.61) 2.80 (0.81-9.63) 1.98 (0.93-4.25) 
NSAIDs     
Any 1.25 (0.76-
2.05) 
1.63 (0.96-2.76) 1.32 (0.75-2.33) 1.48 (1.04-2.12) 
None 0.03 (0.00-
2.53) 
2.75 (0.66-11.5) 4.49 (0.74-27.2) 4.32 (1.05-17.8) 
Aspirin     
Any 0.50 (0.14-
1.77) 
0.97 (0.16-5.75) 1.36 (0.25-7.60) 1.90 (0.69-5.26) 
None 1.15 (0.69-
1.92) 
1.78 (1.07-2.96) 1.56 (0.89-2.75) 1.63 (1.11-2.36) 
* Calculated with Cox regression model with adjustment for age at PCa diagnosis, tumor Gleason grade and 
stage, PSA at diagnosis and FinRSPC study arm. 
** P for interaction = 0.022 in the group with diabetic fasting blood glucose level 
*** P for interaction by statin use = 0.019  
 
 
Impact of change in fasting blood glucose level after initiation of antidiabetic drug 
use 
Change in blood glucose level after initiation of antidiabetic drug use did not clearly modify the risk 
association (Supplementary table 1); diabetic blood glucose level was associated with increased 
risk for PCa death.  However, confidence intervals were wide and statistical significance was not 
reached. 
Supplementary table 1. Risk of prostate cancer death by blood glucose level in relation to effectiveness of 
anti-diabetic medication (no change in blood glucose level as the reference point). Cohort population of 
1,770 men with prostate cancer diagnosed within Finnish Randomized Trial of Screening for Prostate 
Cancer. 
 Risk of prostate cancer death 
 Blood glucose level shift after anti-diabetic medication 
 HR (95%CI)age-adjusted HR (95%CI)multivariable-adjusted* 
 Level fell Level rose Level fell Level rose 
All diabetic drugs 
combined 
3.57 (1.44-8.87) 1.91 (0.69-5.26) 5.71 (2.12-15.4) 2.02 (0.68-5.96) 
 Insulin 3.28 (0.73-14.8) 4.77 (0.85-26.7) 4.14 (0.67-25.6) 7.75 (0.84-71.3) 
Sulfonylurea 
Compounds 
1.95 (0.66-5.77) 1.97 (0.52-7.46) 1.00 (0.30-3.31) 1.00 (0.21-4.72) 
Glitazone - - - - 
Metformin 2.07 (0.75-5.69) 1.24 (0.40-3.86) 3.21 (0.97-10.7) 1.27 (0.37-4.33) 
* Calculated with Cox regression model with adjustment for age at PCa diagnosis, tumor Gleason grade and 
stage, PSA at diagnosis and FinRSPC study arm. 
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Lag-time analyses 
Risk estimates remained increased similarly increased in 1-year and 5-year lag-time analyses 
(Table 5). In 10-year and 20-year lag-time analyses no increased risks were observed, but the 
confidence intervals were wide. 
 
 
Table 5. Long-term association between fasting blood glucose level and prostate cancer death in lag-time 
analysis (multivariable adjusted*). 
  Lag time 
 Main analysis 1yr 5yrs 10yrs 20yrs 
Fasting 
blood 
gluose 
level 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Normal Ref Ref Ref Ref Ref 
IGT 1.50 (0.87-
2.56) 
2.07 (1.21-
3.54) 
2.03 (1.14-
3.62) 
1.03 (0.43-
2.48) 
0.97 (0.09-
10.7) 
Diabetic 1.67 (1.18-
2.36) 
1.90 (1.31-
2.75) 
1.51 (1.02-
2.24) 
1.22 (0.70-
2.12) 
1.33 (0.33-
5.35) 
* Calculated with Cox regression model with adjustment for age at PCa diagnosis, tumor Gleason grade and 
stage, PSA at diagnosis and FinRSPC study arm. 
 
 
Risk of starting endocrine therapy 
Post diagnostic diabetic blood glucose measurements were associated with an increased risk of 
starting endocrine therapy (multivariable adjusted HR 1.38, 95% CI 1.18-1.62). Nonetheless, 
direction of change in blood glucose level after initiation of endocrine therapy had no association 
with prostate cancer survival (Supplementary tables 2 and 3). 
Supplementary table 2. Risk of initiation of endocrine therapy as the primary treatment by blood glucose 
level (normoglycemic level as the reference point). Cohort population of 1,770 men with prostate cancer 
diagnosed within Finnish Randomized Trial of Screening for Prostate Cancer. 
 Risk of initiation of endocrine therapy 
 HR (95%CI)age-adjusted HR (95%CI)multivariable-adjusted* 
 IGT Diabetic IGT Diabetic 
All prostate 
cancer cases 
1.02 (0.79-1.34) 1.41 (1.20-1.65) 1.04 (0.80-1.36) 1.38 (1.18-1.62) 
*Calculated with Cox regression model with adjustment for age at PCa diagnosis, tumor Gleason grade and 
stage, PSA at diagnosis and FinRSPC study arm. 
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Supplementary table 3. Risk of prostate cancer death by reaction of blood glucose level after initiation of 
endocrine therapy (no change in blood glucose level as the reference point). Cohort population of 1,770 men 
with prostate cancer diagnosed within Finnish Randomized Trial of Screening for Prostate Cancer. 
 Risk of prostate cancer death 
 Blood glucose level shift after initiation of endocrine therapy 
 HR (95%CI)age-adjusted HR (95%CI)multivariable-adjusted* 
 Level fell Level rose Level fell Level rose 
All endocrine 
therapy cases 
0.97 (0.60-1.59) 0.64 (0.38-1.10) 0.84 (0.50-1.40) 0.59 (0.34-1.02) 
*Calculated with Cox regression model with adjustment for age at PCa diagnosis, tumor Gleason grade and 
stage, PSA at diagnosis and FinRSPC study arm. 
 
 
DISCUSSION 
 
Diabetic fasting blood glucose levels after PCa diagnosis are associated with an increased risk of 
PCa death. IGT was generally not associated with risk increase. When stratified by tumor 
characteristics, the risk was modified by tumor stage, the association being stronger among men 
with localized PCa. Blood glucose level before PCa diagnosis had no association with PCa 
mortality. 
Previous studies on this topic are scarce. Most earlier studies have evaluated self-reported 
diabetes or relied on antidiabetic medication use. In our study the definition of diabetes was made 
by measured blood glucose levels, therefore we were more likely to catch also untreated diabetes. 
Indeed, the risk increase by diabetic glucose level was strongest in men who were not antidiabetic 
drug users.  Thus, antidiabetic treatment likely affects the cancer risks associated with diabetes, 
suggesting that the optimal way to study diabetes as cancer risk factor includes also non-treated 
diabetics. We were able to evaluate long-term associations between glucose level and PCa 
survival, and level after PCa diagnosis. This allowed more comprehensive analysis of diabetes as 
condition compared to previous studies   
A meta-analysis containing 17 cohort studies found an increased risk of PCa death among patients 
with pre-existing diabetes mellitus (RR=1.29) (10). Similar results were presented by another meta-
analysis consisting of 11 cohort studies (RR=1.26) (11). Furthermore, a cohort consisting of 11,920 
participants found comparable risk association with diabetes mellitus and PCa progression 
(RR=1.23) (12). Our study supports these findings.  
Similar to our study, a weak correlation between hyperglycaemia and PCa death has been 
previously reported in men with intolerance for oral glucose load (13). The study cohort in the earlier 
study was similarly sized as ours, but the mean follow-up time after PCa diagnosis was longer (27 
vs 9.9 years). However, the blood glucose level groups were stratified by study population-specific 
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quartiles, whereas we used clinical cut-points for IGT and diabetes, producing greater 
generalizability.  
Previously, increased overall cancer mortality has been reported in diabetic patients (11). One 
possible explanation could be more aggressive tumor types among diabetics. A previous cohort 
study reported an increased risk of high-grade and metastatic PCa in hyperglycaemic participants 
(14). Another cohort study found an association between high HbA1c-levels and higher Gleason 
scores in diabetic PCa patients (15). However, a previous case-control study showed no association 
between diabetes and PCa aggressiveness (16). Similarly, we have previously observed no 
association between antidiabetic drug use and Gleason score in the FinRSPC study population (17).  
Diabetes has also been associated with lower serum PSA levels, which may affect the risk 
association; in a cohort of Finnish operatively managed PCa patients, diabetic men had more high-
grade disease despite similar PSA levels compared to non-diabetic (18). However, CaPSURE-study 
reported no association between diabetes mellitus and aggressive PCa in patients managed with 
radical prostatectomy (19). 
Increased availability of glucose in the bloodstream supports and fuels rapid cancer cell 
proliferation (11). High blood glucose levels have been proposed to activate genes regulating cell 
proliferation and migration in vitro, increasing their expression in cancer cells (20). High blood 
glucose has also been linked to decreased apoptosis (11). We have previously reported a link 
between SNPs in the genes of the glucose metabolic pathway and PCa risk and prognosis, further 
supporting importance of glucose metabolism for PCa progression (21). Thus, PCa may be more 
aggressive and exhibit higher proliferative activity in diabetics compared to normoglycemic men, 
leading to worse survival as observed in our study. Nevertheless, we did observe the survival 
difference after adjustment for tumor grade, thus hyperglycemia is likely also an independent risk 
factor for PCa progression. 
In type II diabetes mellitus, hyperinsulinemia accompanies persistently elevated blood glucose 
levels due to insulin resistance.  Hyperinsulinemia contributes to tumor growth due to mitogenic 
effects on cells. Insulin sensitizes cells to other growth factors, such as insulin-like growth factors 
(IGFs), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). 
Thus, insulin increases cancer cell proliferation leading to faster tumor growth (22). Insulin stimulates 
the production of IGF-1 in the liver, which further stimulates cell proliferation and inhibits apoptosis. 
Cancerous cells have a high expression of the IGF-1 receptor gene and high circulating IGF-1 
levels associate with poorer prognosis in cancer patients (23). Insulin also inhibits the production of 
insulin-like growth factor binding proteins (IGFBP – I and II), which bind and inhibit IGF-1. Without 
IGFBP, circulating active IGF-1 is more abundant, which results in increased tumor growth (23). 
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Our study cohort was fairly large and contained extensive information on participant and tumor 
characteristics. Particularly information of usage of anti-diabetic medication within the study cohort 
allowed us to analyse the effect of anti-diabetic drugs and its relation to risk of PCa death. In 
addition to fasting blood glucose levels, we also analysed the relation of HbA1c-levels and PCa 
death, eliminating informational bias that would be inevitable if only one-time measurements were 
used. Furthermore, we used the clinical blood glucose level cut points to divide the study cohort 
into normoglycemic, IGT, and diabetic, enhancing external comparability of our results. 
Our study has also weaknesses. The study cohort lacks information on lifestyle factors, such as 
smoking, diet, and amount of exercise, which may affect PCa progression and cause confounding 
(24, 25, 26). However, their role as risk factors for prostate cancer progression is not well established.  
Additionally, we did not have data on correlates of hyperglycaemia such as hyperinsulinemia or 
IGF-1 levels, which ultimately could be the drivers of the association found between a high fasting 
blood glucose levels and the increased risk of PCa death. 
In conclusion, diabetic fasting blood glucose levels are associated with poorer PCa outcomes 
especially among men with localized cancer. Our findings support the role of blood glucose level 
as risk factor for progression of PCa. 
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